Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Treatment Pattern, Clinical Outcome and Healthcare Resource Utilization Associated With Chinese Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Retrospective Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03509896

Enrollment

463

Registered

2018-04-26

Start date

2017-11-30

Completion date

2019-09-28

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Chronic Phase, Philadelphia Chromosome

Brief summary

Observational medical record review of newly diagnosed CML-CP participants in China

Interventions

OTHERNon-Interventional

Non-Interventional

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Ph+ CML-CP patients who were diagnosed between August 1, 2014 to August 1, 2016 * 18 years or older at time of diagnosis

Exclusion criteria

* Participants once enrolled in any interventional clinical trial for CML * Participants whose records are not available Other protocol defined inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with complete cytogenetic response	2 years	Complete Cytogenetic Response (CCyR): 0% Ph+ cells in metaphase in bone marrow (BM)
Number of participants of each initial dose schema	2 years	—
Starting dose of each first-line agent	2 years	—
Number of participants receiving each first-line treatment option	2 years	—
Number of participants with major molecular response (MMR)	2 years	Major molecular response (MMR) is defined as 3-log reduction in International Scale of BCR-ABL mRNA

Secondary

Measure	Time frame	Description
Distribution of clinical characteristics	2 years	Including health insurance and comorbid conditions
Distribution of demographic characteristics	2 years	Including age, sex, height, weight

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026